Australian government launches review of health and medical research

Tuesday, July 12, 2011 12:18 PM

The Australian government has issued the draft terms of reference for a strategic review of health and medical research, according to PharmaTimes.

The review was first announced May 11 by Minister for Mental Health and Aging Mark Butler. Butler has been consulting with the Association of Australian Medical Research Institutes, the Australian Academy of Science, Universities Australia and the trade association for research-based pharmaceutical companies, Medicines Australia, on developing the terms of reference for the initiative.

The Commonwealth Government has been a consistent supporter of health and medical research through the National Health and Medical Research Council (NHMRC), the draft terms of reference say. The NHMRC allocated Aus$784.9 million across its funding schemes in 2010, while the 2011 federal budget included a 4.3% increase in funding for the Council.

The government has also committed Aus$700 million to building and upgrading health and medical research and training facilities across Australia. In addition, there is significant investment in health and medical research by industry and state governments as well as, to a lesser extent, funding from non-governmental organizations and philanthropists.

The government said the research landscape is changing in the face of a number of trends that have emerged over the last two decades, including a shift in the burden of disease towards chronic and mental health conditions, new knowledge and demand for resources arising from human genome mapping and the revolution in information and communications technologies, the larger infrastructure enabled and required by new and emerging technologies, growing recognition of the importance of translating basic research swiftly into clinical practice, and significant reform in the Australian health sector.

“Whereas Australia has been highly successful in research and development ideas up to the proof-of-concept stage, there are significant opportunities to improve our success in turning these discoveries into commercial ventures, as noted in a number of recent studies,” the preamble to the draft terms of reference states.

The strategic review of health and medical research will focus on optimizing Australia’s capacity to produce world-class health and medical research up to 2020, with reference to issues such as the need for Australia to build and retain internationally competitive capacity across the research spectrum, from discovery to translation; expenditure on, and support for, research in Australia by governments, industry, non-governmental organizations and philanthropists; opportunities to leverage additional investment and support for research through the private sector and philanthropy; the relationship between business and the research sector; strategies to ensure that Australia has the research workforce to meet future challenges and opportunities; opportunities to improve collaboration between the research and clinical sectors; the degree of alignment between Australia’s research and the national burden of disease, health priorities, etc.

The federal government intends to announce the Review Panel and associated Terms of Reference by the end of July. The panel is scheduled to hand in its final report by Aug. 31, 2012.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs